Marquette Sports Law Review Volume 18 Article 2 Issue 1 Fall WADA Drug Testing Standards Richard H. McLaren Follow this and additional works at: http://scholarship.law.marquette.edu/sportslaw Part of the Entertainment and Sports Law Commons Repository Citation Richard H. McLaren, WADA Drug Testing Standards, 18 Marq. Sports L. Rev. 1 (2007) Available at: http://scholarship.law.marquette.edu/sportslaw/vol18/iss1/2 This Article is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. For more information, please contact
[email protected]. ARTICLES WADA DRUG TESTING STANDARDS* RICHARD H. MCLAREN** I. INTRODUCTION The recently completed Floyd Landis' decision represents the most extensive and intensive examination to date of the laboratory procedures in use in World Anti-Doping Agency (WADA) accredited laboratories. Earlier cases have challenged the testing procedures 2 as, for example, in erythropoietin (EPO), 3 nandrolone, and homologous blood transfusions, 4 but none match the challenge in the Landis case, which went far beyond the testing methodology for the detection of testosterone. Originally delivered on September 28, 2007, at the National Sports Law Institute's annual conference at Marquette University, which was titled "The Increasing Globalization of Sports: Olympic, International and Comparative Law & Business Issues." LL.M., London, 1972; LL.B., University of Western Ontario, 1971; H.B.A., University of Western Ontario, 1968; Member of International Court of Arbitration for Sport; Chairman of the Independent International Commission of Inquiry on Doping Control; Past Co-Chief Arbitrator for ADRsportRED, a body dealing with Canadian sports at the national level; Past Chairman of the Association of Tennis Professionals Anti-Doping Tribunal; Co-founder of Sport Solution, an athlete advocacy association.